MedTrace Logo

Esophageal Hypersensitivity Study in Patients With Gastroesophageal Reflux Disease (GERD)

NCT01019928 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 14

Last updated 2012-11-09

Study results available
· View outcomes & findings →

Summary

The purpose of the study is to compare sensitivity of visceral pain in the esophagus using different pain stimuli.

Conditions

  • Sensitivity in Esophagus

Interventions

DRUG

AZD1386

95 mg, oral solution, single dose

DRUG

Placebo to AZD1386

Placebo, oral solution, single dose

Sponsors & Collaborators

Principal Investigators

  • Marie Sundin · AstraZeneca R&D, Mölndal, Sweden

  • Peter Funch-Jensen,, MD, PhD · Aarhus Hospital, Dept of Surgical Gastroenterology, Aarhus, Denmark

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-11-30
Primary Completion
2011-01-31
Completion
2011-01-31

Countries

  • Denmark
  • Sweden

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01019928 on ClinicalTrials.gov